Thomas Christély
About
Thomas Christély is from Zurich, Zurich, Switzerland. Thomas is currently Chief Executive Officer at MetrioPharm AG, located in Zurich, Switzerland. Thomas also works as Chairman of the Supervisory Board at Müller-Spreer AG, a job Thomas has held since Jan 2000. In Thomas's previous role as a Managing Director/Chief Financial Officer at MYR Pharmaceuticals, Thomas worked in Bad Homburg until Sep 2021. Prior to joining MYR Pharmaceuticals, Thomas was a Managing Partner/CEO at ARCADUS Pharma GmbH and held the position of Managing Partner/CEO at Velten near Berlin. Prior to that, Thomas was a CEO at Silence Therapeutics AG (Berlin)+COO and later CEO of its holding Silence Therapeutics plc (London) from Jan 2001 to Jan 2012. Thomas started working as CEO/CFO at Internetz AG, Hamburg in Hamburg, Germany in Jan 2000. From Jan 1996 to Jan 2000, Thomas was COO/CFO, Senior VP at OXO Chemie Inc., San Francisco. Prior to that, Thomas was a Managing Partner COO/CFO at Löschen & Partner, Hamburg/Moskau, based in Hamburg/Moscow from Jan 1992 to Jan 1996. Thomas started working as M&A Adviser at Enskilda Securities, London in Jan 1989.
If you’re looking for Thomas Christely's email address, you can find it on finalscout.com. Finalscout is a professional database with more than 500 million business professionals and 200 million company profiles.
Thomas Christély's current jobs
MetrioPharm AG (www.metriopharm.com) is a Swiss biotech company developing first-in-class auto-regulated immune modulators targeting the pathologically dysregulated mitochondrial metabolism in macrophages. MetrioPharm's platform of oral small molecules has demonstrated preclinical & clinical efficacy (3 Phase II studies) in several inflammatory and infectious diseases with an excellent safety profile. As a monotherapy, MetrioPharm's lead candidate MP1032 produces therapeutic effects similar to corticosteroids (cortisone-based therapeutics), but without serious side effects. MP1032 in combination with ultra-low dose corticosteroids has the potential to replace the current standard of care with high dose corticosteroids (cortisone-based therapeutics) - with increased efficacy and reduced side effects. MP1032 has demonstrated synergistic/supra-additive effects in combination with an ultra-low dose of corticosteroids, creating a new class of "super corticosteroids" that are more effective and have no serious side effects. For more than 60 years, there have been no major advances in achieving such corticosteroid-sparing therapy and thereby reducing corticosteroid-specific side effects. In addition, MP1032 has demonstrated broad host-directed antiviral and antibacterial activity in preclinical studies.
Real estate development company focused on the construction of office buildings and hotels in Germany for clients such as SAP, Microsoft, Ernst & Young and major hotel groups.
Thomas Christély's past jobs
A German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis D (HDV) and B (HBV) infections. The company has been sold to Gilead Sciences, Inc. for €1.45bn (€1.15bn plus €300m) in March 2021. I started as employee no. 5.
A pharmaceutical wholesaler in Velten near Berlin with a focus on specialty pharmaceuticals and clinical trial supplies.
A technology leader in the development of RNA interference (RNAi) therapeutics with applications in oncology and respiratory diseases. The company is listed on the London Stock Exchange since its reverse IPO in 2005.
Public venture capital company listed on the German "Geregelter Markt" focusing on investments in Internet companies, founded in 1999 by its strategic investors M.M. Warburg & Co, partners of Bain & Company (Germany) Inc. and other investors. The company was sold to a publicly traded competitor in 2001.
Started this biotech company in San Francisco as employee no. 1 to lead the clinical and regulatory development of OXO Chemie's platform drug WF10 for HIV (Phase III in the US and Canada) and for HCV and respiratory diseases. In addition, I remained COO/CFO & Senior VP of OXO Chemie AG, Fribourg, CH - a pharmaceutical company and parent company of Oxo Chemie Group. Oxo Chemie Group was sold to a Canadian strategic investor in 2000.
An investment company focused on wood processing in Russia. I initiated and managed 3 Russian joint ventures with a total of 850 employees. In addition, we sold 5 turnkey wood processing plants (previously acquired in Germany) to Russian customers. I arranged the corresponding financing (e.g. European Bank for Reconstruction and Development, Russian-American Entreprise Fund, Deutsche Entwicklungsgesellschaft, etc.) for Russian buyers of these wood processing plants.
Swedish investment bank of Skandinaviska Enskilda Banken (SEB), part of the Wallenberg Group. I worked mainly on Scandinavian-German cross-border transactions.
Worked in Directorate General XV on the Commission's policy on European tax and corporate law.